Rufinamide
Small molecule
Evidence outlook
Approved: Epilepsy, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs
- Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00334958 NCT00334958 · Epilepsy This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011. The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis. Registry: NCT00334958 | 3 | Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96) 2009-05-20 | Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). | Partial signal | link ↗ |
View 2 more trials
NCT01146951 NCT01146951 · Lennox-Gastaut Syndrome Participants were randomized to quadruple-blind rufinamide or placebo, with 59 entering treatment and 58 included in the full analysis set. The primary clinical endpoint was met, with a statistically significant reduction in tonic-atonic seizure frequency, but the small sample limits the strength of the evidence. Registry: NCT01146951 | 3 | Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)) 2011-08 | Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)): Rufinamide (E2080) -24.2 Percent Change (range -93.5 to 27.2) | Placebo -3.25 Percent Change (range -81.6 to 151.9) | Partial signal | link ↗ |
NCT01405053 NCT01405053 · Lennox-Gastaut Syndrome This was a randomized, active-controlled trial, but it was open-label with no blinding, had a small sample size (37 randomized, only 12 in the comparator arm) and heavy dropout (only 15 and 4 completers respectively), and its primary endpoint was a behavioral checklist (CBCL) score rather than a seizure-control measure. The primary statistical comparison between arms was not significant, so this trial does not demonstrate a positive effect of rufinamide on its chosen primary endpoint. Registry: NCT01405053 | 3 | Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period (End of Treatment Period (up to approximately Week 106)); Change From Baseline in CBCL Total Problem T-Scores at End of 2-year Treatment Period (Baseline and End of Treatment Period (up to approximately Week 106)) 2015-11-02 | Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period (End of Treatment Period (up to approximately Week 106)): Rufinamide 55.7 score on a scale (Standard Deviation 15.81) | Any Other Approved Antiepileptic Drug 54.8 score on a scale (Standard Deviation 4.5) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Voltage-gated sodium channel drugs
Eslicarbazepine acetate, Fosphenytoin, Lamotrigine, Oxcarbazepine (Oxtellar XR), Oxcarbazepine (Trileptal) and 1 more. Compare all 7 Voltage-gated sodium channel drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rufinamide: this drug | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.